This company will set the stage for larger, more developed companies to go public in January. But it has too much to prove for its IPO to warrant a buy recommendation.

You must subscribe to Danny Brody’s Cannabis Inner Circle to view this content. To learn more and access special member pricing contact our VIP team at 1-866-298-7257. 

Sign In

Enter your details below.